Crispr Therapeutics shares tumble after significant earnings miss
Investing.com - BofA Securities upgraded Godrej Consumer Products (NSE:GOCP) Ltd. (GCPL:IN) from Neutral to Buy with a price target of INR1,315.00, citing favorable risk-reward following recent stock correction.
The stock has fallen approximately 22% from its peak in September 2024 and about 8% from recent highs around fourth-quarter results, according to BofA Securities. The firm maintained its price objective and earnings estimates while noting improving business trends reflected in the first-quarter trading update.
BofA expects growth acceleration to become more evident in the second half of fiscal year 2026, supported by a benign base and emerging commodity tailwinds. The firm highlighted that a 20% correction in PFAD (Palm Fatty Acid Distillate) should positively impact earnings and competitive dynamics in the second half.
The investment bank views Godrej Consumer as a beneficiary of portfolio reshaping efforts, with approximately one-third of its India business now coming from non-soaps and non-home insecticide categories that are growing in strong double digits, particularly liquid detergents and sexual wellness products.
BofA Securities projects Godrej Consumer will achieve consolidated revenue and EPS CAGR of 9% and 17% respectively over FY25-28E, which it considers better than the sector average, while noting mixed overseas trends with potential competitive challenges in Indonesia offset by positive restructuring results in Africa.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.